Subacute myelo-optic neuropathy | |
---|---|
Specialty | Neurology |
Subacute myelo-optic neuropathy (SMON) is an iatrogenic disease of the nervous system [1] leading to a disabling paralysis, blindness and even death. [2] Its defining manifestation was as an epidemic in Japan during the 1960s: the Japanese government estimated 11,000 were affected; however, the College of Medicine at the University of Tokyo put the number at 30,000, citing a lack of preservation of medical records for longer than five years and a lack of cooperation from doctors as the reasons for the discrepancy. [3] On August 3, 1978, the Tokyo District Court ruled that the cause of SMON is Clioquinol. Its manufacturer, Ciba-Geigy, has publicly stated that "Medical products manufactured and sold by us have been responsible for the occurrence of [SMON] in Japan, we extend our apologies." [3]
SMON was first observed and diagnosed in Sweden 1966, by the pediatrician and neurologist Olle Hansson. [4] Clioquinol was marketed as a prophylaxis to tourist diarrhoea. Dr. Olle Hansson was in the front line, fighting for a ban of clioquinol. Doctors in many countries boycotted Ciba-Geigy for many years. Not until 1985 was the pharmaceutical withdrawn. Dr Hansson died a few months later. The day of his death, May 23, is observed as the Anti-Hazardous Drug Day in several parts of the world.[ citation needed ]